{
    "clinical_study": {
        "@rank": "78752", 
        "arm_group": [
            {
                "arm_group_label": "Endoscopic Variceal Ligation", 
                "arm_group_type": "Experimental", 
                "description": "Endoscopic Variceal Ligation every 3 weeks till eradication"
            }, 
            {
                "arm_group_label": "Carvedilol", 
                "arm_group_type": "Active Comparator", 
                "description": "Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD"
            }
        ], 
        "brief_summary": {
            "textblock": "Every patient with HCC with main portal vein thrombosis will be screened for presence of\n      large esophageal varices and will be randomised between non-selective beta blocker versus\n      primary endoscopic variceal ligation. They will be followed to assess the rate of reduction\n      of index bleed rate as well as survival difference between the groups."
        }, 
        "brief_title": "Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma With Portal Vein Thrombosis", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Hemorrhage", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of cirrhosis with Hepatocellular carcinoma and portal vein thrombosis\n\n          -  Presence of large oesophageal varices or small with high risk\n\n        Exclusion Criteria:\n\n          -  Any contra-indication to beta-blockers\n\n          -  Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months\n\n          -  High risk gastric varices\n\n          -  Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for\n             portal hypertension\n\n          -  Significant cardio or pulmonary co-morbidity\n\n          -  Any extrahepatic malignancy\n\n          -  Patients with past history of variceal bleed\n\n          -  Patients with non-tumor portal vein thrombosis\n\n          -  Refusal to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659346", 
            "org_study_id": "ILBS-HCC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endoscopic Variceal Ligation", 
                "description": "Endoscopic Variceal Ligation every 3 weeks till eradication.", 
                "intervention_name": "Endoscopic Variceal Ligation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Carvedilol", 
                "description": "Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD", 
                "intervention_name": "Carvedilol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic beta-Antagonists", 
                "Carvedilol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "shasthry@gmail.com", 
                "last_name": "Dr SM Shasthry, MD", 
                "phone": "011-46300000"
            }, 
            "contact_backup": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "011-46300000", 
                "phone_ext": "1032"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver and Biliary Sciences"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis", 
        "overall_contact": {
            "email": "shasthry@gmail.com", 
            "last_name": "Dr SM Shasthry, MD", 
            "phone": "011-46300000"
        }, 
        "overall_contact_backup": {
            "email": "bhardwaj.ankit3@gmail.com", 
            "last_name": "Dr Ankit Bhardwaj", 
            "phone": "011-46300000", 
            "phone_ext": "1032"
        }, 
        "overall_official": {
            "affiliation": "Institute of Liver and Biliary Sciences", 
            "last_name": "Dr SM Shasthry, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "First Variceal Bleeding", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Procedure related complications.", 
                "safety_issue": "Yes", 
                "time_frame": "2 Years"
            }, 
            {
                "measure": "Reduction   of risk of bleeding by 50 %", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}